|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | More anxious than depressed:prevalence and correlates in a 15-nation study of anxiety disorders in people with type 2 diabetes mellitus显示文摘Background Anxiety disorder, one of the highly disabling, prevalent and common mental disorders, is known to be more prevalent in persons with type 2 diabetes mellitus (T2DM) than the general population, and the comorbid presence of anxiety disorders is known to have an impact on the diabetes outcome and the quality of life. However, the information on the type of anxiety disorder and its prevalence in persons with T2DM is limited. Aims To assess the prevalence and correlates of anxiety disorder in people with type 2 diabetes in different countries. Methods People aged 18-65 years with diabetes and treated in outpatient settings were recruited in 15 countries and underwent a psychiatric interview with the Mini-International Neuropsychiatric Interview. Demographic and medical record data were collected. Results A total of 3170 people with type 2 diabetes (56.2% women;with mean (SD) duration of diabetes 10.01 (7.0) years) participated. The overall prevalence of anxiety disorders in type 2 diabetic persons was 18%;however, 2.8% of the study population had more than one type of anxiety disorder. The most prevalent anxiety disorders were generalised anxiety disorder (8.1%) and panic disorder (5.1%). Female gender, presence of diabetic complications, longer duration of diabetes and poorer glycaemic control (HbA1c levels) were significantly associated with comorbid anxiety disorder. A higher prevalence of anxiety disorders was observed in Ukraine, Saudi Arabia and Argentina with a lower prevalence in Bangladesh and India. Conclusions Our international study shows that people with type 2 diabetes have a high prevalence of anxiety disorders, especially women, those with diabetic complications, those with a longer duration of diabetes and poorer glycaemic control. Early identification and appropriate timely care of psychiatric problems of people with type 2 diabetes is warranted. | Santosh K Chaturvedi Shayanth Manche Gowda Helal Uddin Ahmed Fahad D Alosaimi Nicola Andreone Alexey Bobrov Viola Bulgari Giuseppe Carra Gianluca Castelnuovo Giovanni de Girolamo Tomasz Gondek Nikola Jovanovic Thummala Kamala Andrzej Ki Nebojsa Lalic Dusica Lecic-Tosevski Fareed Minhas Victoria Mutiso David Ndetei Golam Rabbani Suntibenchakul Somruk Sathyanarayana Srikanta Rizwan Taj Umberto Valentini Olivera Vukovic Wolfgang Wolwer Larry Cimino Arie Nouwen Cathy Lloyd Norman Sartorius | 2019 | General Psychiatry2019，32，4： | 11 |
| 2 | Leishmania donovani whole cell antigen delivered with adjuvants protects against visceral leishmaniasis in vervet monkeys (Chlorocebus aethiops)显示文摘In a previous immunogenicity and efficacy study in mice,montanide ISA 720(MISA)was indicated to be a better adjuvant than bacillus calmette guerin vaccine(BCG)for a Leishmania vaccine.In the present study,we report the safety,immunogenicity and efficacy of Leishmania donovani(L.donovani)sonicated antigen delivered with alum-BCG(AlBCG),MISA or monophosphoryl lipid A(MPLA)in vervet monkeys following intradermal inoculums.Vaccinated and control animals were challenged with virulent L.donovani parasites and the parasitic burden was determined.Only animals vaccinated with alum-BCG adversely reacted to the inoculum by producing ulcerative erythematous skin indurations.Non-parametric ANOVA followed by a post test showed significantly higher IgG antibodies,and revealed the presence of lymphoproliferative and interferon gamma responses in both AlBCG+Ag and MISA+Ag as compared to the MPLA+Ag or other groups(P < 0.001).We conclude that L.donovani sonicated antigen containing MISA is safe and is associated with protective immune response against Leishmania donovani infection in the vervet monkey model. | Joshua Muli Mutiso John Chege Macharia Evans Taracha Michael Muita Gicheru | 2012 | The Journal of Biomedical Research2012，26，1： | 2 |
| 3 | Development ofLeishmania vaccines:predicting the future from past and present experience显示文摘Leishmaniasis is a disease that ranges in severity from skin lesions to serious disfigurement and fatal systemic infection. Resistance to infection is associated with a T-helper-1 immune response that activates macrophages to kill the intracellular parasite in a nitric oxide-dependent manner. Conversely, disease progression is generally associated with a T-helper-2 response that activates humoral immunity. Current control is based on chemotherapeutic treatments which are expensive, toxic and associated with high relapse and resistance rates. Vaccination remains the best hope for control of all forms of the disease, and the development of a safe, effective and affordable antileishmanial vaccine is a critical global public-health priority. Extensive evidence from studies in animal models indicates that solid protection can be achieved by immunization with defined subunit vaccines or live-attenuated strains of Leishmania. However, to date, no vaccine is available despite substantial efforts by many labo-ratories. Major impediments in Leishmania vaccine development include: lack of adequate funding from national and international agencies, problems related to the translation of data from animal models to human disease, and the transition from the laboratory to the field. Furthermore, a thorough understanding of protective immune responses and generation and maintenance of the immunological memory, an important but least-studied aspect of antiparasitic vaccine development, during Leishmania infection is needed. This review focuses on the progress of the search for an effective vaccine against human and canine leishmaniasis. | Joshua Muli Mutiso John Chege Macharia Maria Ndunge Kiio James Maina Ichagichu Hitler Rikoi Michael Muita Gicheru | 2013 | The Journal of Biomedical Research2013，27，2： | 2 |
| 4 | Ven- triculoperitoneal shunt complications : a three - year ret- rospective study in a Kenyan national teaching and refer- ral hospital显示文摘 | Mwachaka P M Obonyo N G Mutiso B K | 2010 | Pediatr Neurosurg2010，46，1： | 1 |
| 5 | Ventriculoperi- toneal shunt complications: a three-year retrospective study in a Kenyan national teaching and referral hospital 显示文摘 | Mwachaka PM Obonyo NG Mutiso BK | 2010 | Pediatr Neurosurg2010，46，1： | 1 |
| 6 | Integrating simulations and experiments to predict sheet resistance and optical transmittance in nanowire films for transparent conductors显示文摘 | Mutiso R M Sherrott M C Rathmell A R | 2013 | Acs Nano2013，7，9： | 1 |
| 7 | Reverse sural island flap in coverage of defects lower third of leg:a series of nine cases显示文摘 | KHAINGA S O GITHAE B MUTISO V M | 2007 | East Afr Med J2007，84，1： | 1 |
| 8 | Ethnobotanical studies of medicinal plants used by Traditional Health Practitioners in the management of diabetes in Lower Eastern Province, Kenya显示文摘 | Lucia K. Keter Patrick C. Mutiso | 2011 | Journal of Ethnopharmacology2011，，1： | 1 |
| 9 | Ethnobotanical studies of medicinal plants used by Traditional Health Practitioners in the management of diabetes in Lower Eastern Province, Kenya显示文摘 | Keter LK Mutiso PC | 2012 | J Ethnopharmacol2012，139，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员